机构：[1]Department of Hematology, Yunnan Research Center of Hematology, the First Affiliated Hospital of Kunming Medical University, Kunming, P. R.China内科科室医技科室血液内科医学影像中心CT室昆明医科大学附属第一医院[2]Department of Laboratory Medicine, Yuhuangding Hospital of Qingdao University, Yantai, P. R. China[3]Department of Clinical Laboratory, Yunnan Institute of Experimental Diagnosis, the First Affiliated Hospital of Kunming Medical University, YunnanKey Laboratory of Laboratory Medicine, No. 295, Xichang Road, Kunming City, Yunnan Province, P. R. China医技科室医学检验科昆明医科大学附属第一医院[4]Department of Thoracic Surgery, the First Affiliated Hospital of Kunming Medical University, Kunming, P. R. China外科科室胸外科昆明医科大学附属第一医院[5]Department of Urinary Surgery, the First People’s Hospital of Kunming City, Kunming, P. R. China
Tripartite motif-containing 22 (TRIM22) is reported to participate in numerous cellular activities. Recent studies confirm that TRIM22 is a target gene for P53, and inhibits clonogenic growth of leukemic U-937 cells. The current study aims to discover the effect of TRIM22 in progression of human chronic myeloid leukemia (CML) and explore the related mechanism. TRIM22 was knocked down by siRNA transfection in CML cell K562. We observed that TRIM22 knockdown decreased proliferation and invasion in K562 cells. TRIM22 knockdown significantly induced cell cycle arrest by regulating the level of CDK4, Cyclin D1, P70S6K, and P53 in K562 cell. Moreover, loss of TRIM22 also promoted apoptosis through modulation of Bcl-2, Bax and active Caspase 3 in K562 cell. Furthermore, we demonstrated that TRIM22 knockdown inhibited the activation of PI3K/Akt/mTOR pathway by decreasing the level of the phosphorylated form p-Akt and p-mTOR in K562 cell. In conclusion, loss of TRIM22 suppresses the progression and invasion of CML through regulation of PI3K/Akt/mTOR pathway, suggesting that TRIM22 might be as a potential target for the treatment strategy of CML.
第一作者机构：[1]Department of Hematology, Yunnan Research Center of Hematology, the First Affiliated Hospital of Kunming Medical University, Kunming, P. R.China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Li Liyin,Qi Yanhua,Ma Xiaobo,et al.TRIM22 knockdown suppresses chronic myeloid leukemia via inhibiting PI3K/Akt/mTOR signaling pathway[J].CELL BIOLOGY INTERNATIONAL.2018,42(9):1192-1199.doi:10.1002/cbin.10989.
